Compositions and methods for transdermal oxybutynin therapy

Abstract

The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and / or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.

Description

[0001] priority information

[0002] This application claims priority based on U.S. Patent Application Serial No. 10 / 286,381, filed November 1, 2002, which was filed March 15, 2002, with Application Serial No. 10 / 098,752, which is a continuation-in-part of U.S. Patent Application Serial No. 09 / 559,711, filed April 26, 2000, which is incorporated herein by reference All of the above applications are incorporated herein. field of invention

[0003] The present invention relates to compositions and methods for minimizing adverse drug sensations associated with oxybutynin therapy. Thus, the present invention covers the fields of pharmaceutical sciences, medicine and other health sciences. Background of the invention

[0004] Oral oxybutynin therapy is commonly used to treat various forms of overactive bladder and urinary incontinence. In particular, oxybutynin is effective in treating bladder disorders of neuropathic origin. The reduction of these disorders is attributed to...

Images